Medicus Pharma Stock Swings After Skin Cancer Treatment Results
Medicus Pharma Ltd. (NASDAQ:MDCX) shares surged to a high of $1.61 before falling during Thursday’s premarket session following the release of topline data from its Phase 2 clinical trial for SKNJCT-003.
The Phase 2 study evaluated the safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.
BCC is the most common, slow-growing, and highly curable form of skin cancer, usually caused by long-term UV exposure.
The stock’s movement comes as the company reported a 73% clinical clearance rate, which may support an end-of-phase meeting with the FDA in the first half of 2026.
Skin Cancer Data
The topline results from the SKNJCT-003 Phase 2 clinical study indicated that the 200µg dose cohort achieved a 73% clinical clearance rate and a 40% histological clearance rate.
The study involved 90 patients with nodular basal cell carcinoma (BCC).
These results are seen as decision-grade evidence of clinical activity, reinforcing the company’s strategy to advance its development programs and pursue strategic partnerships.
The company aims to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses and procedural observations.
Medicus Pharma Technical Analysis
Currently, the stock is trading 8.70% above its 20-day simple moving average (SMA), reflecting short-term strength, while it is 12.5% below its 100-day SMA, indicating some longer-term challenges.
Over the past 12 months, shares have decreased significantly, and they are currently positioned closer to their 52-week lows than highs.
The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold.
Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in momentum in the near term.
- Key Resistance: $1.75
- Key Support: $1.25
MDCX Price Action: Medicus Pharma shares were down 21.01% at $1.09 during premarket trading on Thursday. The stock is trading near its 52-week low of $0.91.
Image via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nifty 50 Is Still Down 4.91% in 2026, So Why Does Citi See 13% Upside?
US Dollar Index: Fed path and CPI focus – Deutsche Bank
VIPMidterm Elections Conclude, Anthropic Initiates IPO
1. Cross-asset performance diverged this week. Between the October 30 and November 6 closes, the S&P 500 fell 2.68%, the Nasdaq 100 dropped 4.91%, and BTC lost 1.88%. Gold and silver rose 4.51% and 5.79%, respectively, while the Hang Seng gained 5.10%. Sharp declines in crude oil and some Asian equity indexes showed how differently assets responded to growth, policy, and event risks. 2. Democrats won majorities in both chambers of Congress in the US midterm elections, and markets rallied before reversing. We focus on actual changes in fiscal negotiations, key committee arrangements, and local industrial policy, especially data-center approvals, energy costs, and the pace of capital expenditure. We do not map party outcomes directly to asset direction. 3. The pullback in technology stocks has put returns on AI investment under renewed scrutiny. Whether rapid growth can cover financing, construction, and ongoing compute costs is becoming a key valuation test. For related positions, monitor policy implementation, customer capital expenditure, and cash collection together, and do not read a one-day rebound as a sign that the pressure has passed. 4. Anthropic's IPO preparations are putting the growth quality, operating profitability, and funding needs of AI model companies under public-market scrutiny. Valuations discussed for the offering are not final pricing, and participating in related products also requires assessing fees, allocation methods, asset rights, and trading restrictions. Assets in focus: BTC, the Nasdaq 100, crude oil, and gold, along with key earnings from companies including CSCO, AMAT, and CEG
Asian Stocks Rebound, Nikkei Up 3.4%, but Can They Lead Wall Street?
Crypto prices
More
